Endometrial Cancer Clinical Trials in Orlando, Florida

14 studies are recruiting for endometrial cancer in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cel…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002), Orlando, Florida
    Locations
    264 in total
    Run by
    Merck Sharp & Dohme LLC
  2. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Florida Cancer Specialists - Lake Nona, Orlando, Florida
    Locations
    20 in total
    Run by
    Terremoto Biosciences Inc.
  3. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Advent Health, Orlando, Florida
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc
  4. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute - Lake Nona Florida, Orlando, Florida
    Locations
    26 in total
    Run by
    SystImmune Inc.
  5. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Orlando, Florida
    Locations
    255 in total
    Run by
    AstraZeneca
  6. Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

    This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
    Locations
    6 in total
    Run by
    ArriVent BioPharma, Inc.
  7. Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

    This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.

    Stage
    Not phased
    Ages
    18 and older
    Site
    ADVENTHEALTH (Data collection only), Orlando, Florida
    Locations
    18 in total
    Run by
    Memorial Sloan Kettering Cancer Center
  8. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Florida Cancer Specialists, Orlando, Florida
    Locations
    82 in total
    Run by
    Artios Pharma Ltd
  9. Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

    This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following pla…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Orlando, Florida
    Locations
    320 in total
    Run by
    AstraZeneca
  10. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Florida Cancer Specialists - Lake Nona, Orlando, Florida
    Locations
    28 in total
    Run by
    Jazz Pharmaceuticals
  11. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

    The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Orlando Health, Orlando, Florida
    Locations
    24 in total
    Run by
    Mayo Clinic
  12. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sara Cannon Research Institute Lake Nona, Orlando, Florida
    Locations
    39 in total
    Run by
    SystImmune Inc.
  13. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dren Investigational Site, Orlando, Florida
    Locations
    10 in total
    Run by
    Dren Bio
  14. A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

    The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

    Stage
    Phase 2
    Ages
    18 to 70
    Site
    Orlando Health, Orlando, Florida
    Locations
    12 in total
    Run by
    Iovance Biotherapeutics, Inc.

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.